Journey Medical Corp Announces New Journey with the Experts Video Featuring Aurora Shehu Wingrove, MD — Journey Medical Corporation

Dr. Shehu Wingrove discusses androgenetic alopecia, a dermatologic condition with more than three million cases in the United States per year

 

SCOTTSDALE, Ariz.March 19, 2021PRLog — Journey Medical Corporation (Journey Medical) today released a new Journey with the Experts video featuring Aurora Shehu Wingrove, MD, PhD, a board-certified dermatologist with Advanced Dermatology and Cosmetic Surgery in Beaver, Pennsylvania. Dr. Shehu Wingrove discusses androgenetic alopecia with Journey Medical, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.

Androgenetic alopecia, also known as male or female pattern baldness, is the permanent loss of hair from the scalp. To view the Journey with the Experts video featuring Dr. Shehu Wingrove, please visit https://vimeo.com/515455785/33094bfce1.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

About Journey Medical Corporation

Journey Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets five products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.

About Aurora Shehu Wingrove, MD, PhD

Dr. Shehu Wingrove earned her MD and PhD (Physiology and Biophysics) at the University of Illinois in Chicago. She was awarded the Ervin Ernos Award for Excellence in the Basic Sciences and the Outstanding Dissertation Award in Life Sciences. She completed a medical internship at the University of Chicago, Northshore Healthcare System, where she received the Service Value Award. Dr. Shehu Wingrove then completed her residency in Dermatology at the University of Pittsburgh Medical Center in Pittsburgh, PA. She is a member of the American Academy of Dermatology, the Women’s Dermatologic Society and the American Society for Dermatologic Surgery. For additional information about Dr. Shehu Wingrove, please visit https://www.advancedderm.com/about-us/our-providers/aurora-shehu-wingrove-md.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.

LEAVE A REPLY

Please enter your comment!
Please enter your name here